Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Targeting Tyrosine Kinase Receptors

Michael Deininger, MD, PhD

Blood (2013) 122 (21): SCI-25.

https://doi.org/10.1182/blood.V122.21.SCI-25.SCI-25

Published: 2013

Journal Articles

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

Blood (2011) 118 (21): 3766.

https://doi.org/10.1182/blood.V118.21.3766.3766

Published: 2011

Journal Articles

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

Jorge Cortes, MD, Moshe Talpaz, MD, Dale Bixby, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W. Flinn, MD, PhD, Michael Mauro, MD, Thomas O'Hare, PhD, Simin Hu, PhD, Rebecca Kan, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 210.

https://doi.org/10.1182/blood.V116.21.210.210

Published: 2010

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Hanna Jean Khoury, MD, Michael J. Mauro, MD, Yousif Matloub, MD, Tai-Tsang Chen, PhD, Erkut Bahceci, MD, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 1128.

https://doi.org/10.1182/blood.V114.22.1128.1128

Published: 2009

Journal Articles

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Michael Deininger, MD, PhD, François-Xavier Mahon, MD, Francois Guilhot, MD, Giuseppe Saglio, MD, Philipp le Coutre, MD, Arnon Nagler, MD, Anna D'Emilio, MD, Fabio Stagno, Enrica Morra, MD, Andrea Piccin, MD, Sarit E. Assouline, MD, Elisabetta Abruzzese, Valeria Santini, MD, Fabrizio Pane, MD, Pilar Giraldo, MD, Laura Antolini, PhD, Maria Grazia Valsecchi, PhD, Carlo Gambacorti-Passerini, MD

Blood (2009) 114 (22): 1108.

https://doi.org/10.1182/blood.V114.22.1108.1108

Published: 2009

Journal Articles

Defining Extrinsic Survival Pathways in CML Progenitor Cells.

Ryan Mackenzie, Jennifer Snead, PhD, Jonathan VanDyke, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 941.

https://doi.org/10.1182/blood.V114.22.941.941

Published: 2009

Journal Articles

The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia.

Anupriya Agarwal, PhD, Ryan Mackenzie, Dorian LaTocha, Kavin Vasudevan, Eduardo Firpo, Marc Loriaux, Keiichi Nakayama, Brian J. Druker, MD, James M Roberts, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 3276.

https://doi.org/10.1182/blood.V114.22.3276.3276

Published: 2009

Journal Articles

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

Karl J. Aichberger, MD, PhD, Angela G. Fleischman, MD, PhD, Shirin Doratotaj, MD, Thomas G.P. Bumm, MD, Richard T. Silver, MD, Thomas G. Deloughery, MD, Heike L. Pahl, PhD, Brian J. Druker, MD, Christopher J. Burns, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 2917.

https://doi.org/10.1182/blood.V114.22.2917.2917

Published: 2009

Journal Articles

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

Jorge Cortes, MD, Moshe Talpaz, MD, Michael Deininger, MD, PhD, Neil Shah, MD, PhD, Ian W Flinn, MD, Michael J. Mauro, MD, Thomas O'Hare, PhD, Natalie Spinos, Simin Hu, PhD, Lori Berk, Narayana Narasimhan, PhD, Victor M. Rivera, PhD, Tim Clackson, PhD, Frank Haluska, MD, PhD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 643.

https://doi.org/10.1182/blood.V114.22.643.643

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill H Chang, MD, PhD, Vincent T Bicocca, Stephen T Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. DenBoer, MSc, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Jason R Gotlib, MD, MS, Michael Deininger, MD, PhD, Brian J. Druker, MD

Blood (2009) 114 (22): 3978.

https://doi.org/10.1182/blood.V114.22.3978.3978

Published: 2009

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Blood (2009) 114 (22): 2199.

https://doi.org/10.1182/blood.V114.22.2199.2199

Published: 2009

Journal Articles

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Anna Vales, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Edgar Selzer, MD, Michael Deininger, MD, PhD, Brian J. Druker, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 1987.

https://doi.org/10.1182/blood.V106.11.1987.1987

Published: 2005

NARROW

Targeting Tyrosine Kinase Receptors

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.

Defining Extrinsic Survival Pathways in CML Progenitor Cells.

The Oncogenic Role of Tumor Suppressor Protein p27 in Ph+ Chronic Myeloid Leukemia.

Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.

A Phase 1 Trial of Oral AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Other Hematologic Malignancies: First Results of Safety and Clinical Activity against T315I and Resistant Mutations.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only